{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T09:10:10Z","timestamp":1718701810608},"reference-count":19,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T00:00:00Z","timestamp":1468886400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2016,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>An 11\u2010year\u2010old male was diagnosed with chronic\u2010phase chronic myeloid leukemia (CML) in 1998 and received therapy with interferon\u2010\u03b12b and low\u2010dose cytarabine. In 6 years, he progressed to lymphoid blast crisis and received induction chemotherapy with prednisolone, vincristine, daunorubicin, and<jats:sc>l<\/jats:sc>\u2010asparaginase concomitantly with imatinib 400\u00a0mg\/day, and continuation with vincristine + prednisolone, cytarabine + etoposide, vincristine +<jats:sc>l<\/jats:sc>\u2010asparaginase, cyclophosphamide + etoposide, and 6\u2010mercaptopurine + methotrexate. Complete molecular response (MR) was achieved and therapy was continued with imatinib 800 mg\/day. He relapsed to chronic\u2010phase CML after interruption of imatinib and regained MR after its restart. The patient is alive 17.5 years after CML diagnosis and 11.5 years after lymphoid blast crisis.<\/jats:p>","DOI":"10.1002\/pbc.26148","type":"journal-article","created":{"date-parts":[[2016,7,19]],"date-time":"2016-07-19T13:03:49Z","timestamp":1468933429000},"page":"2243-2245","source":"Crossref","is-referenced-by-count":1,"title":["Very long survival in complete cytogenetic remission in an adolescent with lymphoid blast crisis of chronic myeloid leukemia after treatment with intensive ALL\u2010directed chemotherapy combined with continuous imatinib"],"prefix":"10.1002","volume":"63","author":[{"given":"Alexey","family":"Maschan","sequence":"first","affiliation":[{"name":"Dmitri Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation Moscow Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galina","family":"Novichkova","sequence":"additional","affiliation":[{"name":"Dmitri Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation Moscow Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Miakova","sequence":"additional","affiliation":[{"name":"Dmitri Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation Moscow Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Persiantseva","sequence":"additional","affiliation":[{"name":"Dmitri Rogachev Federal Research Center for Pediatric Hematology, Oncology and Immunology, Russian Federation Moscow Russia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,7,19]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"1497","article-title":"A minute chromosome in human chronic granulocytic leukemia","volume":"132","author":"Nowell PC","year":"1960","journal-title":"Science"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/243290a0"},{"key":"e_1_2_6_4_1","first-page":"20","article-title":"Cytogenetics of chronic myelogenous leukemia","volume":"25","author":"Bernstein R.","year":"1988","journal-title":"Semin Hematol."},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-06-292433"},{"issue":"5","key":"e_1_2_6_6_1","first-page":"1517","article-title":"An evidence\u2010based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology","volume":"94","author":"Silver RT","year":"1999","journal-title":"Blood"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199707243370402"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.12.4064.bloodjournal84124064"},{"issue":"4","key":"e_1_2_6_9_1","first-page":"513","article-title":"; Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long\u2010term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"91","author":"Gratwohl A","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)90733-6"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.5"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00021-6"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2007.12.002"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13068"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25123"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1996.tb00488.x"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428199609051745"},{"issue":"5","key":"e_1_2_6_18_1","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1111\/bjh.12079","article-title":"Dasatinib combined with weekly administration of vincristine as effective therapy in sudden or resistant Ph+ lymphoid blast crisis of chronic myeloid leukaemia","volume":"159","author":"Breccia M","year":"2012","journal-title":"Br J Haematol"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.057513"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23624"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.26148","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.26148","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.26148","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T08:57:51Z","timestamp":1718701071000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.26148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,19]]},"references-count":19,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["10.1002\/pbc.26148"],"URL":"https:\/\/doi.org\/10.1002\/pbc.26148","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,19]]}}}